Search Results - "Schewe, K."

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance‐associated substitutions in hepatitis C genotype 3 infection by von Felden, J., Vermehren, J., Ingiliz, P., Mauss, S., Lutz, T., Simon, K. G., Busch, H. W., Baumgarten, A., Schewe, K., Hueppe, D., Boesecke, C., Rockstroh, J. K., Daeumer, M., Luebke, N., Timm, J., Schulze zur Wiesch, J., Sarrazin, C., Christensen, S.

“…Summary Background Twelve weeks of the pangenotypic direct‐acting antiviral (DAA) combination sofosbuvir/velpatasvir (SOF/VEL) was highly efficient in patients…”
Get full text

Summary of German‐Austrian HIV PrEP guideline by Spinner, CD, Lang, GF, Boesecke, C, Jessen, H, Schewe, K, Stellbrink, Hans‐Jürgen, Esser, Stefan, Haberl, Annette, Römer, Katja, Plettenberg, Andreas, Rockstroh, Jürgen, Scholten, Stefan, Weber, Christoph, Haas, Bernhard, Lehmann, Clara, de Leuw, Philipp, Brockmeyer, Norbert, Schmiedel, Stefan, Kaiser, Rolf, Kaiser, Rolf, Marcus, Ulrich, Schafberger, Armin, Schwarze, Siegfried, Feustel, Nicholas, Langanke, Harriet, Claass, Johanna

“…Objectives HIV Pre‐Exposure prophylaxis (PrEP) is a strategy to reduce HIV transmission in people at risk. Aim of this first German‐Austrian PrEP guideline is…”
Get full text

Does Sofosbuvir (SOF)/Velpatasvir (VEL) with or without Ribavirin (RBV) change the landscape of therapy in chronic hepatitis C genotype 3 (GT 3) infection? – Results from the GErman hepatitis C COhort (GECCO) by Christensen, S, Ingiliz, P, Schewe, K, Rockstroh, J, Hueppe, D, Baumgarten, A, Lutz, T, Schmutz, G, Berger, F, Kimhofer, T, Busch, H, Mauss, S

Get full text

Effect of eradicating hepatitis C on alanine aminotransferase levels by Mauss, S, Boesecke, C, Berger, F, Ingiliz, P, Simon, K.G, Hueppe, D, Lutz, T, Schewe, K, Baumgarten, A, Rockstroh, J, Christensen, S

Get full text

High rates of quinolone-resistant strains of Shigella sonnei in HIV-infected MSM by Hoffmann, C., Sahly, H., Jessen, A., Ingiliz, P., Stellbrink, H.-J., Neifer, S., Schewe, K., Dupke, S., Baumgarten, A., Kuschel, A., Krznaric, I.

“…Purpose There is increasing evidence that shigellosis is a predominantly sexually transmitted disease among men who have sex with men (MSM) and that infection…”
Get full text

Parameters Associated with Treatment Failure with Direct Acting Antivirals against the Hepatitis C Virus (HCV) – Results Fro the German Hepatitis C Cohort (GECCO) by Ingiliz, P, Christensen, S, Kimhofer, T, Hueppe, D, Schewe, K, Lutz, T, Boesecke, C, Simon, K.-G, Baumgarten, A, Mauss, S

Get full text

Relapse and Treatment-Emergent RAVS with DAA-Based Regimens in Hepatitis C Virus (HCV) Mono- or Human Immunodeficiency Virus (HIV)-HCV Co-Infected Patients – a Real Concern in Clinical Practice? Results from the German Hepatitis C Cohort (GECCO) by Christensen, S, Ingiliz, P, Schewe, K, Rockstroh, J, Hueppe, D, Baumgarten, A, Lutz, T, Schmutz, G, Simon, K.G, Busch, H, Kimhofer, T, Mauss, S

Get full text

P0835 : German multicenter cohort on sofosbuvir-based treatments in HCV mono- and HIV/HCV co-infected patients (GECOSO) by Ingiliz, P, Christensen, S, Hueppe, D, Lutz, T, Schewe, K, Boesecke, C, Simon, K.G, Schmutz, G, Baumgarten, A, Busch, H, Mauss, S

Get full text

Etomidate unmasks intraadrenal regulation of steroidogenesis and proliferation in adrenal cortical cell lines by Hahner, S, Stürmer, A, Fassnacht, M, Hartmann, R W, Schewe, K, Cochran, S, Zink, M, Schirbel, A, Allolio, B

“…To characterize intraadrenal adaptations for inhibition of cortisol synthesis, we analyzed the effects of etomidate (ETO) on steroid hormone secretion and…”
Get more information

The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients by Knechten, H, Stephan, C, Mosthaf, F A, Jaeger, H, Carganico, A, Lutz, T, Schewe, K, Mayr, C, Wolf, E, Wellmann, E, Tappe, A

“…We have previously reported data from the German cohort of the multinational observational prospective RAINBOW survey which assessed the tolerability and…”
Get full text

Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS by Plettenberg, A, Brockmeyer, N. H, Haastert, B, Michalik, C, Dupke, S, Schewe, K, Rausch, M, Hower, M, Ulmer, A, Wolf, E, Lorenzen, T, Arendt, G, Jansen, K

“…Purpose Hitherto, studies on highly active antiretroviral therapy (HAART) initiation have shown partly inconsistent results. Our study investigated the…”
Get full text

Mycobacterium microti Llama-Type Infection Presenting as Pulmonary Tuberculosis in a Human Immunodeficiency Virus-Positive Patient by HORSTKOTTE, Matthias A, SOBOTTKA, Ingo, SCHEWE, Carl K, SCHÄFER, Peter, LAUFS, Rainer, RÜSCH-GERDES, Sabine, NIEMANN, Stefan

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort by Koegl, C, Wolf, E, Hanhoff, N, Jessen, H, Schewe, K, Rausch, M, Goelz, J, Goetzenich, A, Knechten, H, Jaeger, H, Becker, W, Becker-Boost, I, Berzow, D, Beiniek, B, Brust, J, Shcuster, D, Dupke, S, Fenske, S, Gellermann, H J, Gippert, R, Hartmann, P, Hintsche, B, Jaegel-Guedes, E, Gölz, J, Koelzsch, J, Helm, E B, Knecht, G, Lochet, I, Gute, P, Mauruschat, S, Mauss, S, Miasnikov, V, Mosthaf, F A, Freiwald, M, Reuter, B, Schalk, H M, Schappert, B, Schnaitmann, E, Schneider, I, Schüler-Maué, W, Schuler, C, Seidel, T, Starke, W, Ulmer, A, Müller, M, Weitner, I, Zamani, C, Hanmond, A, Ross, K, Bottlaender, A, Hoffmann, C, Dix, A, Schneidewind, A, Lademann, M

“…To investigate if early treatment of primary HIV-1 infection (PHI) reduces viral set point and/or increases CD4 lymphocytes. Analysis of two prospective…”
Get full text

Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases by Vogel, M., Bieniek, B., Jessen, H., Schewe, C. K., Hoffmann, C., Baumgarten, A., Kroidl, A., Bogner, J. R., Spengler, U., Rockstroh, J. K.

“…Studies on hepatitis C virus (HCV) monoinfected patients suggest high sustained treatment response rates of up to 98% when interferon monotherapy is…”
Get full text

Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany? by Bischoff, Jenny, Boesecke, Christoph, Ingiliz, Patrick, Berger, Florian, Simon, Karl-Georg, Lutz, Thomas, Schewe, Carl K., Schulze zur Wiesch, Julian, Hueppe, Dietrich, Christensen, Stefan, Mauss, Stefan, Baumgarten, Axel, Rockstroh, Jürgen K.

“…GOALS AND BACKGROUND:International guidelines recommend prioritized treatment initiation in hepatitis C virus (HCV)-infected patients with advanced liver…”
Get full text

Safety and Efficacy of a Saquinavir-Containing Antiretroviral Regimen in Previously ART-Naïve or Pretreated but Protease Inhibitor-Naïve HIV-Positive Patients by Knechten, H, Stephan, C, Mosthaf, F. A, Jaeger, H, Lutz, T, Cargnico, A, Stoehr, A, Koeppe, S, Mayr, C, Schewe, K, Wolf, E, Wellmann, E, Tappe, A

“…Background: The RAINBOW survey is a multinational observational study assessing the tolerability and efficacy of ritonavir-boosted saquinavir (SQV/r), using…”
Get full text

On the unification of query algebras and their extension to rational tree structures by Schewe, K.-D.

“…In order to come to a unification of existing query algebras, especially for object bases, it is necessary to understand the semantic differences between…”
Get full text

Design theory for advanced datamodels by Schewe, K.-D.

“…Argues in favour of a design theory for advanced data models, such as object-oriented models. We start from basic design desiderata for databases, independent…”
Get full text

Has increased rollout of DAA therapy decreased the burden of late presentation and advanced liver disease in patients starting HCV therapy in Germany? by Rockstroh, J., Boesecke, C., Ingiliz, P., Florian, B., Simon, K.-G., Thomas, L., Schewe, K., Schulze, J., Wiesch, Z., Hüppe, D., Christensen, S., Mauss, S.

Get full text

THU-432 - Has increased rollout of DAA therapy decreased the burden of late presentation and advanced liver disease in patients starting HCV therapy in Germany? by Rockstroh, J., Boesecke, C., Ingiliz, P., Florian, B., Simon, K.-G., Thomas, L., Schewe, K., Schulze, J., Wiesch, Z., Hüppe, D., Christensen, S., Mauss, S.

Get full text